Arcturus Therapeutics (ARCT) Tops Q4 EPS by 25c

Arcturus Therapeutics (NASDAQ: ARCT) reported Q4 EPS of ($1.47), $0.25 better than the analyst estimate of ($1.72). Revenue for the quarter came in at $5.8 million versus the consensus estimate of $14.72 million.

For earnings history and earnings-related data on Arcturus Therapeutics (ARCT) click here.

You May Also Be Interested In

• Walmart (WMT) Tops Q2 EPS by 7c, Beats on Revenue; Offers FY27 EPS Guidance
• Youdao, Inc. (DAO) Tops Q2 EPS by 50c
• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance